glp-1/gip/gcg receptor agonist Frontiers LY3437943, a novel triple glucagon,

We also describe the development of incretin-based pharmacotherapy, starting with exendin- 4 and ending with the identification of multi-incretin hormone receptor agonists, which appear to be the next major step in the fight against T2DM and obesity

7.40.8 Eq/min/gkw)

Evaluating what the research shows about GLP-1 medications and depression and suicidal ideation.

Gastrointestinal side effects are a little more common in the oral version than in the injectables

Tirzepatide 15 mg led to higher discontinuation rate of study medication due to adverse events regardless of comparator, while all tirzepatide doses were safe in terms of serious adverse events and mortality

Semaglutide was removed in February 2025